Brice Wagner, PA
Medical · Covington, LANPI 1568037232
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 162 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 24.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,397 and has fallen 69.0% since, to $433 in 2025.
Across 162 payments — averaging $24.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$937
- Johnson & Johnson$368
- Novo Nordisk$280
- Merck$280
- Sanofi-aventis U.S. LLC$251
- Bayer$227
- plus $2K from 25 others
What the payments were for
- Food & beverage$3,912100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 39 | $937 |
| Johnson & Johnson | 15 | $368 |
| Novo Nordisk | 13 | $280 |
| Merck | 10 | $280 |
| Sanofi-aventis U.S. LLC | 9 | $251 |
| Bayer | 9 | $227 |
| Pfizer | 10 | $209 |
| E.r. Squibb & Sons, L.L.C. | 6 | $186 |
| Amarin Pharma, Inc. | 10 | $171 |
| Novartis | 9 | $144 |
| Esperion Therapeutics, Inc. | 9 | $143 |
| Abbott | 1 | $135 |
| Cardiovascular Systems Inc. | 1 | $109 |
| Jazz Pharmaceuticals Inc. | 1 | $85 |
| Baxter Healthcare | 1 | $43 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Lilly USA, LLC | 2 | $28 |
| Atricure, Inc. | 1 | $26 |
| Edwards Lifesciences | 1 | $23 |
| Philips North America LLC | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $19 |
| GSK | 1 | $17 |
| Bard Peripheral Vascular, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
| Silk Road Medical, Inc. | 1 | $15 |
| AstraZeneca | 1 | $13 |
| Irhythm Technologies, Inc. | 1 | $12 |
| CMP Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$597
- VERQUVO$230
- ETERNA$135
- XARELTO$125
- Ozempic$122
- Kerendia$112
- Diamondback Peripheral$109
- Diamondback Coronary$109
- MULTAQ$106
- CAMZYOS$101
How this compares
$3,912 in reported general payments places this provider in the 80th percentile of 253 medical providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 139 | $118,380 |
| Repatha SureclickEvolocumab | 86 | $59,530 |
| XareltoRivaroxaban | 56 | $54,632 |
| MounjaroTirzepatide | 19 | $26,898 |
| EntrestoSacubitril/Valsartan | 17 | $23,165 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $18,324 |
| OzempicSemaglutide | 14 | $14,883 |
| FarxigaDapagliflozin Propanediol | 13 | $13,991 |
| Testosterone Cypionate | 82 | $5,099 |
| Rosuvastatin Calcium | 261 | $3,436 |
| Celecoxib | 21 | $1,791 |
| Testosterone | 22 | $1,462 |
| Spironolactone | 118 | $1,296 |
| ClopidogrelClopidogrel Bisulfate | 153 | $1,287 |
| Ezetimibe | 51 | $1,232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $209 | $118,380139 claims |
| Johnson & JohnsonXarelto | $368 | $54,63256 claims |
| Lilly USA, LLCMounjaro | $28 | $26,89819 claims |
| NovartisEntresto | $144 | $23,16517 claims |
| GSKTrelegy Ellipta | $17 | $18,32421 claims |
| Novo NordiskOzempic | $280 | $14,88314 claims |
| AstraZenecaFarxiga | $13 | $13,99113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 253 medical providers in Louisiana.
Other medical in Covington
- Sydney FussellCovington$16K
- Courtney CoyleCovington$6K
- Misty BreakfieldCovington$5K
- Kristi RobertBaton Rouge$486K
- Vickie RiceBaton Rouge$19K
- Mary McFerrenShreveport$16K
- Rachel RhinehartJefferson$16K
- Thomas BriscoeLafayette$13K
- Seth HendrixShreveport$12K
- Jessica PelusoNatchitoches$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.